INTRODUCTION

Anemia of chronic kidney disease (CKD)
becomes increasingly prevalent and severe as kidney function declines [1] , with over 90% of patients who require renal replacement therapy becoming anemic [2] . In CKD, anemia results primarily from decreased production of endogenous erythropoietin (EPO) by the kidney [3] . The introduction of exogenous erythropoiesis-stimulating agents (ESAs) to clinical practice has transformed the care of patients with CKD, by ameliorating anemia, reducing transfusion requirements, and improving quality of life [4] .
Over the last 25 years, several originator and biosimilar ESAs have been introduced for the management of CKD anemia, starting with the first generation short-acting recombinant erythropoietin agents (epoetin alfa and beta) and latterly with two longer-acting molecules, darbepoetin alfa (DA) and methoxy polyethylene glycol-epoetin beta (PEG-Epo), which combine a significantly increased halflife and lower binding affinity for the EPO receptor, allowing them to stimulate erythropoiesis for longer periods and to be administered less frequently [5, 6] . DA, launched in 2001 [5, 7] , contains 5 N-linked oligosaccharide chains, rather than the 3 contained in short-acting epoetins, which
confer an approximately threefold longer serum half-life and mean residence time, allowing extended inter-dosing intervals [6] .
Pharmacokinetic studies have shown that the mean ± SD terminal half-life of DA is 21 ± 7.5 h when administered intravenously (IV) [7] . DA can be administered once a week (QW) or once every 2 weeks (Q2W) to hemodialysis patients.
Longer-acting PEG-Epo contains a chemical bond between an amino group present in epoetin beta and methoxy polyethylene glycol (PEG) butanoic acid; the addition of PEG is responsible for an increase in serum half-life of epoetin beta, and in CKD patients on dialysis the terminal half-life of PEG-Epo after IV administration is 134 h [6, 8] . PEG-Epo was approved in 2009 for administration Q2W or once a month (QM) to patients on dialysis [5, 8] 
METHODS
The AFFIRM study was designed as a retrospective, longitudinal cohort analysis to estimate the DCR in a population of hemodialysis patients achieving comparable Hb after switching from IV DA to IV PEG-Epo in a real-world setting. The study sample comprised adult patients (age C18 years) with CKD who received maintenance hemodialysis between January 2008 and August 2011 and whose ESA treatment was switched from IV DA to IV PEG-Epo. As the study was entirely retrospective, ESA switching and dose conversion were performed without reference to a study protocol and there was no protocoldriven intervention in the clinical management of patients. This article does not contain any studies with human or animal subjects performed by any of the authors.
Patients were required to fulfill the following criteria for study entry: switched from treatment with DA to treatment with PEG-Epo at least 7 months before study enrollment; receipt of hemodialysis for at least 12 months prior to switching; receipt of IV DA for at least 7 months immediately prior to switching; receipt of at least 1 dose of PEG-Epo after switching; and provision of informed consent, according to local requirements. Patients were excluded if they had participated in any interventional study within 30 days before the 7-month period preceding the switch or at any subsequent time up to 7 months after the switch.
The enrolling dialysis centers were situated 
Statistical Methods
The primary outcome (DCR) for each patient was calculated as the mean weekly dose of PEGEpo during the post-switch EP divided by the mean weekly dose of DA during the pre-switch EP. Due to the skewed nature of the dosing data, mean weekly ESA doses were reported using geometric means; these were derived by calculating the arithmetic mean of the data transformed on the natural logarithmic scale.
By definition, the DCR could not be calculated for patients ineligible for the DCR analysis as these did not have the necessary parameters recorded in both EPs. The data from this study were analyzed using SAS Statistical Software v9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 302 eligible patients were enrolled at 14 European hemodialysis centers, with 57% of patients enrolled at 10 French sites, 18% at 2 Spanish sites, 17% at 1 UK site, and 8% at 1 German site. Of the 302 patients enrolled, 206 (68%) were included in the DCR analysis.
Reasons for exclusion of 96 enrolled patients from the DCR analysis are presented in Fig. 1 : 21% of the excluded patients had died or were lost to follow-up during the post-switch period; 45% were no longer receiving PEG-Epo by Months ?6 and ?7 post-switch; and 34% had no Hb value reported for one or both EPs.
The baseline (i.e., at time of switch) demographic and clinical characteristics of enrolled patients and those included in and Mutually exclusive categories; patients are censored in the following order: first at death post-switch, then at loss to follow-up post-switch, then at receipt of an ESA other than PEG-Epo, and finally lack of an Hb measurement in either or both EPs. DCR geometric mean maintenance dose conversion ratio, EP evaluation period, ESA erythropoiesis-stimulating agent, Hb hemoglobin, PEG-Epo methoxy polyethylene glycolepoetin beta excluded from the DCR analysis are displayed in Table 1 .
The primary outcome measure, the geometric mean maintenance DCR, was calculated to be 1.17 (95% CI 1.05, 1.29). In an additional analysis performed to assess the sensitivity of this result to the effects of transfusion by excluding those patients who received an RBC transfusion within 90 days prior to or during either evaluation period, the DCR was 1.21 (95% CI 1.09, 1.35).
The regression analysis that examined the relationship between mean weekly ESA doses in the two evaluation periods indicated that the DCR CI confidence interval, DCR dose conversion ratio, Hb hemoglobin, Q1, Q3 interquartile range, Q2W every 2 weeks, QW once weekly
is not linear; a significant (P = 0.008) quadratic term was observed in the regression analysis, indicating that the predicted DCR decreased at higher pre-switch doses of DA (Fig. 2) .
Results of the Bland-Altman analysis investigating the concordance between mean weekly ESA doses in both evaluation periods are presented in Fig. 3 . This analysis indicated that the concordance decreased with increasing dose. The geometric mean weekly ESA dose for those included in the DCR analysis is shown in Fig. 4 , 11.7 g/dL (11.5, 11.9), and 11.4 g/dL (11.3, 11.6), respectively. Tables 2 and 3 , the mean (standard error) monthly Hb remained stable categories by study month. In the month immediately prior to switch, the proportions of patients who had Hb below 10, 10-12, and above 12 g/dL were 7.3%, 54.4%, and 25.7%, respectively, with 12.6% missing. In the first month after switch, these proportions were 10.2%, 48.5% and 37.4%, respectively. By Month 7 post-switch, the proportions of patients with Hb in these ranges were 9.7%, 48.1%, and 30.1%, respectively.
As shown in
Concerning RBC transfusions, 36 patients received a transfusion; 7 were transfused in the pre-switch period only, 4 received a transfusion both pre-and post-switch, and 25 had a transfusion in the post-switch period only.
There were 16 transfusion events in the preswitch period and 48 post-switch, with a total of 34 units transfused pre-switch and 95 units in When multiple assessments were available for a patient, the single assessment closest to center of the interval was used. DCR geometric mean maintenance dose conversion ratio, Hb hemoglobin the post-switch period (Fig. 5) . Logistic regression analysis showed a higher likelihood of a transfusion during the post-switch period among patients with a dose ratio at switching of \1. Of the 29 patients transfused during the post-switch period, 20 had a dose ratio at switch \1, and 9 had a dose ratio at switch C1 (odds ratio 2.39, 95% CI 1.05, 5.44; P = 0.038). The pre-transfusion Hb concentrations were similar for transfusions occurring both pre-and postswitch (Fig. 6) ; the mean (SD) Hb within 14 days prior to transfusion in these periods was 8.8 
DISCUSSION
This paper presents the findings of a retrospective, multi-center, observational study of hemodialysis patients switched from DA to PEG-Epo for the treatment of anemia. The primary finding of the study is that the DCR of PEG-Epo to DA was 1.17 (95% CI 1.05, 1.29). When multiple assessments were available for a patient, the single assessment closest to center of the interval was used. DCR geometric mean maintenance dose conversion ratio, Hb hemoglobin (Fig. 6) Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
